EUVIMEDEUVIMED entdecken
Crossref

Antidepressants and risk of inflammatory bowel disease: A drug-target Mendelian randomization study

Ji-Lin Wang, Ye Hu, Zhi-Jun Cao

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2025.119919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Ji-Lin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive D…. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Inflammatory Bowel Diseases, Antidepressive Agents, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Previous studies have found that antidepressants could reduce the risk of IBD, but the results are controversial. Therefore, a drug-target Mendelian randomization was applied to explore the casual relationship between antidepressants and IBD, aiming to identify new preventive uses for the drugs. METHODS: Target genes corresponding to classic SSRI drugs were obtained from the DrugBank database. eQTL Data was collected from the eQTLGen Consortium database. GWAS data for IBD were retrieved from the FinnGen dataset. The IVW-MR and SMR methods were used for the analysis. Heterogeneity was assessed using the Cochran's Q test, and sensitivity analyses was conducted to verify the reliability of the results. RESULTS: The IVW-MR analysis indicated a significant correlation between SIGMAR1 and risk of IBD, CD and UC. The OR with 95%CI for IBD was 0.925 (0.885-0.968), for CD was 0.91(0.845-0.979), for UC was 0.942(0.895-0.991). The SMR analysis indicated a significant correlation between SLC29A4 and risk of IBD, CD and UC. The OR with 95%CI was 1.524(1.265-1.784) for IBD, 1.767(1.343-2.19) for CD and 1.613(1.316-1.909) for UC. There were no significant genetic associations between serotonin concentration and IBD. The sensitivity analysis suggested no evidence of heterogeneity or pleiotropy among the reported results. CONCLUSION: Activation of SIGMAR1 could reduce the risk of IBD, while activation of SLC29A4 could increase the risk of IBD. Further research is warranted to fully understand the potential role of SSRIs targeted genes in the development and progression of IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mendelian Randomization AnalysisInflammatory Bowel DiseasesAntidepressive AgentsSelective Serotonin Reuptake InhibitorsHumansGenome-Wide Association StudyCrohn DiseasePolymorphism, Single NucleotideGenetic Predisposition to Disease

Stichwörter der Autor:innen

AntidepressantsCrohn's diseaseInflammatory bowel diseaseMendelian randomizationUlcerative colitis

Substanzen

Antidepressive AgentsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong Univers…
  • Department of Gastroenterology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: huye327@126.com.

Förderung

  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Wang, J. L., Hu, Y., & Cao, Z. J. (2025). Antidepressants and risk of inflammatory bowel disease: A drug-target Mendelian randomization study. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119919

Vancouver

Wang JL, Hu Y, Cao ZJ. Antidepressants and risk of inflammatory bowel disease: A drug-target Mendelian randomization study. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119919

BibTeX
@article{Wang2025,
  author = {Wang, Ji-Lin and Hu, Ye and Cao, Zhi-Jun},
  title = {Antidepressants and risk of inflammatory bowel disease: A drug-target Mendelian randomization study},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2025.119919}
}
Kostenlos starten →